ABSTRACT
OBJECTIVE: The aim: To determine the accumulation of heavy metals, namely Cr, Cd, Cu, Pb, Zn by a tumour in correlation with unaffected colon tissue and blood of patients with colorectal cancer. PATIENTS AND METHODS: Materials and methods: The study is based on the results of observation of 180 patients with CRC. The following samples were taken from: the tumor, the colon and blood unaffected by the tumor - during the operative treatment of patients in the surgical department of the communal non-profit enterprise "Precarpathian Clinical Oncology Center of the Ivano-Frankivsk regional council" for 2018-2020. RESULTS: Results: According to the obtained results, the blood of patients with CRC contains much less heavy metals: Pb - 8.6 and 9.3 times less than in the tumour and unaffected by cancer colon, respectively; Cr - 9 and 14.8 times less; Cd - 3.75 and 5 times less; Cu - 1.48 and 1.18 times less than in the tumour and unaffected colon, respectively. Besides, the content of Zn in the blood is 1.04 times higher than in non-cancerous tissue of the colon. CONCLUSION: Conclusions: It can be stated that the highest content of Pb, Cr and Cd was recorded in non-cancerous tissue of the colon of patients with CRC; the highest content of Zn and Cu was revealed tumour tissue.
Subject(s)
Colonic Neoplasms , Metals, Heavy , Humans , Cadmium , Lead , Colonic Neoplasms/surgeryABSTRACT
OBJECTIVE: The aim: To evaluate the early and late results of treatment of rectal cancer patients after special treatment methods with a view to indentifying optimal method of treatment in correlation with the stage of the disease. PATIENTS AND METHODS: Materials and methods: The study is based on the results of observation of 779 patients with stage II, III and IV rectal cancer (RC) who were divided into groups according to the treatment (surgery, surgery + chemotherapy, chemotherapy, surgery + chemotherapy + radiation therapy, radiation therapy + surgery, radiation therapy). RESULTS: Results: According to the results obtained, the overall survival of patients correlates with the stage of rectal cancer: we see the highest percentage of patients' survival in stage II and, accordingly, the lowest - in stage IV in each of the studied time intervals. CONCLUSION: Conclusions: The use of combined and integrated treatment in patients with stages II and stage III and the use of chemotherapy in stage IV RC gives a higher rate of cumulative survival of patients at each of the studied intervals.
Subject(s)
Rectal Neoplasms , Humans , Neoplasm Staging , Rectal Neoplasms/pathology , Rectal Neoplasms/therapyABSTRACT
OBJECTIVE: The aim: To evaluate and analyze early and late results of treatment of patients with rectal cancer after chemotherapy. PATIENTS AND METHODS: Materials and methods: The study is based on the results of observation of 779 patients with stage II, III and IV rectal cancer (RC) who were divided into groups according to the chemotherapy treatment. RESULTS: Results: In the course of chemotherapy treatment of RC patients, most of them received the FOLFOX regimen treatment - 87 patients (43.5%). 40 people (20%) received Mayo regimen. 36 patients (18%) underwent FOLFIRI regimen. Another 33 patients received the XELOX regimen chemotherapy (16.5%). In four cases, patients underwent Tegafur monotherapy (2%). CONCLUSION: Conclusions: The obtained data for patients with stage III RC showed that at all studied time intervals, the highest percentage of surviving patients was recorded in those who received chemotherapeutic treatment according to the FOLFOX regimen. In patients with stage II RC, the most ef f ective was Mejo regimen - 30.7% (survived patients for the 5 year observation).
